AlphAIAlphAI — Financial news for AI agents
stocktwits.comSEP 191 min read$TRAX

TRAX Stock Hits All-Time High — What's Driving The Super Rally?

First Tracks Biotherapeutics (TRAX) shares hit an all-time high after HC Wainwright raised its price target to $44, citing positive clinical results from competitor Forte Biosciences (FBRX). TRAX was up 13% and FBRX over 20% on Friday. Both companies target the CD122 pathway for autoimmune therapies.

Original reporting
stocktwits.com
Published Sep 19, 2026, 12:28 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 19, 2026, 2:54 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$TRAX
Bullish
high confidence
Mentioned
$TRAX
Relevance
7/10
AlphAI data visualization · based on stocktwits.com
Decision brief

The 30-second read

$TRAXBullishHigh
01

Why it matters

The price target increase provides a clear catalyst for short‑term buying, while sector validation could broaden the rally to peers.

02

Market read

TRAX's stock jump reflects both company‑specific analyst action and broader sector momentum in immunology biotech.

03

What to watch

TRAX is not yet testing its lead candidate in vitiligo, and the upcoming Phase 1b celiac data remains uncertain.

Relevance 7/10Novelty 7/10Timing: Friday opening trade

Background

First Tracks Biotherapeutics (TRAX) shares surged after an analyst raised its price target, citing supportive data from competitor Forte Biosciences (FBRX) on the CD122 pathway.

Company-level read

Ticker impact

$TRAXBullishHigh confidence
Context

HC Wainwright raised TRAX price target to $44 from $30, stock jumped ~13% in Friday's opening trade.

Expected impact

Further upside as the new target suggests ~22% upside from current levels.

Evidence & confidence

The upgrade provides a concrete valuation metric and aligns with sector validation from competitor data, likely attracting additional buying pressure.

Market effects

Sector

Positive validation of CD122 pathway may lift other biotech firms developing similar immunomodulatory therapies.

Regional

Boosts US biotech sector sentiment.

Global

Highlights global interest in autoimmune disease treatments.

Counterpoint

What could challenge this read

The rally may be premature if the CD122 pathway fails to deliver late‑stage data, leading to a pull‑back.

Key entities

  • company
    First Tracks Biotherapeutics Inc.

    US‑listed biotech developing CD122 pathway therapies.

  • analyst
    HC Wainwright

    Equity research firm that raised TRAX's price target.

Read at source← All news

Related articles

SEP 16
$TRAXHigh

Why is First Tracks Biotherapeutics stock rallying today?

First Tracks Biotherapeutics (TRAX) rose 4.5% after Guggenheim and UBS initiated coverage with Buy ratings and a $100 price target, citing potential in ANB033 for autoimmune diseases. The FDA granted Fast Track designation, and Phase 1b data is expected in Q4 2026. The Nasdaq and S&P 500 also gained 0.8% and 0.4%, respectively.

investing.com1 min
SEP 16
$TRAXMed

First Tracks Biotherapeutics stock rises on Guggenheim buy rating

First Tracks Biotherapeutics (TRAX) shares rose 3.8% after Guggenheim initiated coverage with a Buy rating and $100 price target, citing confidence in its anti-CD122 target and lead asset ANB033 for autoimmune diseases. Guggenheim analyst Yatin Suneja highlighted the company's unique position as the only publicly traded small-to-mid cap firm developing an anti-CD122 monoclonal antibody.

investing.com1 min
AUG 12
$TRAXMed

First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

First Tracks Biotherapeutics, Inc. (TRAX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update • Completed enrollment for Cohort 1 (gluten challenge) of Phase 1b ANB033 trial in celiac disease (CeD); top-line Cohort 1 data reaffirmed for Q4 2026 • Cohort 2

SEC EDGAR 8-K5 min
JUL 31
$CORTMed

Biotech Stocks At 52-Week Highs- CORT +30%, NEOG +22% & BAX +7% With Quarterly Results, TRAX, XNCR

The following biotech stocks reached 52-week highs on July 30, 2026, driven by key catalysts such as positive quarterly reports or announced settlement agreements. Corcept Therapeutics Incorporated (CORT) Corcept is a biopharmaceutical company engaged in developing medications for metabolic, oncologic, and neurologic diseases. Shares surged over 30% on Thursday to a 52-week high of $122.21.

rttnews.com6 min
JUL 28
$ENTXMed

Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired

Biotech gainers included Entera Bio (ENTX), up 91% after an oversubscribed private placement expected to raise about $275M. Gossamer Bio (GOSS) rose 47% on plans to file a Seralutinib NDA for PAH in Sept 2026 and regain rights from Chiesi. Forte Biosciences (FBRX) jumped 40% on argenx (ARGX) acquisition for $77/share. Omeros (OMER) gained 16% after AstraZeneca’s Ultomiris failed a Phase 3 endpoint.

rttnews.com6 min
JUL 10
$VRAXMed

Top Biotech Gainers: VRAX Jumps 100% After Fosun Deal, FBRX Soars On Vitiligo Data, TRAX On Watch

Biotech stocks rose on company-specific catalysts. Virax Biolabs (VRAX) jumped over 100% after signing an exclusive multi-country supply agreement with Fosun Diagnostics for ImmuneSelect. Forte Biosciences (FBRX) gained about 78% on positive Phase 1b vitiligo data for FB102. First Tracks (TRAX) rose ~56% without news. TransCode (RNAZ) and Connect Biopharma (CNTB) also climbed; Sanuwave (SNWV) fell guidance and expects Q2 revenue of $8.5m to $9.5m.

rttnews.com6 min